Drug Approval | August 12, 2021
Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee
The company is eligible for 12 months exclusivity from launch
The company is eligible for 12 months exclusivity from launch
The company has tied up with OrbiMed as a financial partner for global reach
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The aim is to create new genomics solutions that could combat cancer and advance market access
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Subscribe To Our Newsletter & Stay Updated
